Articles

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

Dong-A University Medical Center, Busan, South Korea
Tata Memorial Hospital, Parel, Mumbai, India
Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Prince Aly Khan Hospital, Mazagaon, Mumbai, India
Chonbuk National University Medical School & Hospital, Jeonju, South Korea
Kyungpook National University Hospital, Daegu, South Korea
Ajou University Hospital, Suwon, South Korea
Ajou University Hospital, Suwon, South Korea
Chonnam National University, Hwasun Hospital, Hwasun, South Korea
Chonnam National University, Hwasun Hospital, Hwasun, South Korea
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
Ulsan University Hospital, Ulsan, South Korea
Hallym University Sacred Heart Hospital, Anyang, South Korea
Pusan National University Hospital, Pusan, South Korea
Pusan National University Hospital, Pusan, South Korea
Dongsan Medical Center, Keimyung University, Daegu, South Korea
St. Vincent Hospital, The Catholic University of Korea, Suwon, South Korea
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Korea University, Guro Hospital, Seoul, South Korea
Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea
Central Research Institute, IL-YANG Pharm. Co. Ltd., Yongin, South Korea
Central Research Institute, IL-YANG Pharm. Co. Ltd., Yongin, South Korea
Central Research Institute, IL-YANG Pharm. Co. Ltd., Yongin, South Korea
Central Research Institute, IL-YANG Pharm. Co. Ltd., Yongin, South Korea
Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea;Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea
Vol. 99 No. 7 (2014): July, 2014 https://doi.org/10.3324/haematol.2013.096776